cvn - cristobal belda iniesta - intheos · residency program, to incorporate them into a 3-year...

Este fichero electrónico (PDF) contiene incrustada la tecnología CVN (CVN-XML). La tecnología CVN de este fichero permite exportar e importar los datos

curriculares desde y hacia cualquier base de datos compatible. Listado de Bases de Datos adaptadas disponible en http://cvn.fecyt.es/

Cristobal Belda IniestaDate of document: 23/07/2014v 1.3.0561ad5f5a2f86f67f36acae0a3ce6385

http://cvn.fecyt.es/

561ad5f5a2f86f67f36acae0a3ce6385

2

Cristobal Belda Iniesta

Surname(s): Belda IniestaName: CristobalDNI: 34802736XDate of birth: 23/12/1971Gender: MaleLand line phone: (+34) 917567984Fax: (+34) 917500193Email: [email protected]

Current professional situation

Name of institution: Instituto Mixto deInvestigación- Escuela Nacional de Sanidad

Type of institution: University Research Institute

Category/position or post: DirectorStart date: 03/04/2014Type of contract: Statutory Type of dedication: Full time

Name of institution: Instituto de Salud Carlos III Type of institution: Public Research BodyDepartment, service, etc.: National School of HealthCategory/position or post: DirectorStart date: 01/03/2014Type of contract: Statutory Type of dedication: Full time

Name of institution: Biomedical Research Institute "Alberto Sols"Category/position or post: Associated InvestigatorStart date: 01/09/2003

Previous posts and activities

Name of institution Category/position or post Start date1 Hospital Universitario Madrid Norte

SanchinarroHead of Thoracic/ Neuro-oncology Division 01/02/2012

2 Severiano Ballesteros Foundation Scientific Director 01/06/2011

3 Universidad San Pablo CEU Assistant Profesor 2011

4 Hospital Universitario La Paz Senior Faculty on Medical OncologyDepartment

09/12/2006

5 Universidad Autónoma de Madrid Assistant profesor 2005

6 Fundación de Investigación HospitalUniversitario La Paz

Rio Hortega 07/12/2003

7 Hospital Universitario La Paz Residency, training on Medical Oncology 30/06/1999


3

1 Name of institution: Hospital UniversitarioMadrid Norte Sanchinarro

Type of institution: Healthcare Institutions

Department, service, etc.: OncologyCity of job: Madrid, Community of Madrid, SpainCategory/position or post: Head of Thoracic/ Neuro-oncology DivisionStart date: 01/02/2012End date: 28/02/2014Type of contract: Permanent employment contractType of dedication: Full timePrimary (UNESCO code): 320101 - CancerologyProfessional activity: Clinical research mainly with drugs in early development stages, translationaloncology and pharmacoeconomy of biomarkers, clinical research and new drugs.

2 Name of institution: Severiano Ballesteros FoundationCategory/position or post: Scientific Director Teaching management: YesStart date: 01/06/2011End date: 28/02/2014Type of contract: colaboraciónType of dedication: Part timeProfessional activity: Global Management of scientific policy of Seve Ballesteros Foundation,cooperation with Cancer Research UK to promote brain tumours research in UK and with CNIO toestablish a permanent research lab for brain tumours research within the CNIO-BBVA program inSpain.Appl. in teaching and/or research: Global Management of scientific policy of Seve BallesterosFoundation, cooperation with Cancer Research UK to promote brain tumours research in UK andwith CNIO to establish a permanent research lab for brain tumours research within the CNIO-BBVAprogram in Spain.

3 Name of institution: Universidad San Pablo CEU Type of institution: UniversityDepartment, service, etc.: Ciencias Clínicas, MedicinaCategory/position or post: Assistant ProfesorStart date: 2011End date: 2014Type of dedication: Part timeAppl. in teaching and/or research: Topics: general pathology, medical pathology 1 and medicalpathology 3 for MD.

4 Name of institution: Hospital Universitario LaPaz


Category/position or post: Senior Faculty on Medical Oncology DepartmentStart date: 09/12/2006, 5 years - 1 month - 18 daysEnd date: 31/01/2012

5 Name of institution: Universidad Autónoma deMadrid

Type of institution: University

Category/position or post: Assistant profesorStart date: 2005, 4 yearsEnd date: 2009

6 Name of institution: Fundación de InvestigaciónHospital Universitario La Paz


Category/position or post: Rio Hortega


4

Start date: 07/12/2003, 3 yearsEnd date: 06/12/2006Professional activity: "Rio Hortega" is a position for MD-PhD Personnel, after finishing theirresidency program, to incorporate them into a 3-year training program on translational and clinicalresearch. This is a very competitive, national and multi- speciality program managed by the SpanishGovernment)

7 Name of institution: Hospital Universitario LaPaz


Category/position or post: Residency, training on Medical OncologyStart date: 30/06/1999, 4 yearsEnd date: 29/06/2003


5

Official training received

University education

University degrees, engineering degrees or master's degrees

1 Official qualification: Médico Especialista vía MIRName of qualification: Médico Especialista en Oncología Médicainstitution issuing the qualification: Ministerio deEducación, Política Social y Deporte

Type of institution: State agency

Date of qualification: 30/06/2003

2 Official qualification: Higher degreeName of qualification: Licenciado en Medicina y Cirugíainstitution issuing the qualification: Universidad deMurcia



Doctorates

Doctorate programme: Programa Oficial de Doctorado en MedicinaUniversity issuing the qualification: UniversidadAutónoma de Madrid



Language skills

Language Speaking Reading WritingFrench Intermediate Advanced Elementary

Catalan Advanced Advanced Intermediate

Spanish Advanced Advanced Advanced

English Advanced Advanced Advanced

Teaching activity


6

Subjects given

1 Qualification: Máster en Biotecnología BiomédicaStart date: 2011 End date: 2012Date of the last time: 2012institution: Universidad Politécnica de Valencia Type of institution: University

2 Qualification: Máster en Evaluación en Innovación Biosanitaria.Start date: 2010 End date: 2012Date of the last time: 2012institution: Universidad de Castilla-La Mancha Type of institution: UniversityFaculty, institute or centre: Facultad de Ciencias Económicas y Empresariales

3 Qualification: Máster Universitario en Cuidados Paliativos y Tratamiento de Soporte del Paciente con CáncerStart date: 2005 End date: 2010Date of the last time: 2010institution: Universidad Autónoma de Madrid Type of institution: UniversityFaculty, institute or centre: Facultad de Medicina

Participation in specialised healthcare training programme

1 Degree of specialisation: Medicina InternaInstitution issuing the qualification: Ministerio deSanidad y Consumo

Type of institution: Administrative Body of the NationalHealth System

Unit: Oncología MédicaTraining start date: 01/09/2003 - 31/01/2012,

2 Degree of specialisation: Oncología MédicaType of participation: Evaluación Anual Residencia para Formación EspecializadaInstitution issuing the qualification: MINISTERIO DE SANIDAD Y CONSUMOUnit: Oncología MédicaTraining start date: 01/09/2003 - 31/01/2012,

3 Degree of specialisation: Oncología RadioterápicaInstitution issuing the qualification: Ministerio deSanidad y Consumo


Unit: Oncología MédicaTraining start date: 01/09/2003 - 31/01/2012,

4 Degree of specialisation: Oncología RadioterápicaInstitution issuing the qualification: Ministerio deSanidad y Consumo


Unit: Oncología MédicaTraining start date: 01/02/2012,


7

Supervision of dissertations and/or final projects

1 Project title: Evaluación de la expresión de Colino-Quinasa como factor pronóstico en el carcinoma no microcíticode pulmónUniversity issuing the qualification: UniversidadAutónoma de Madrid


Doctorate student: Jorge Barriuso FeijooDate of reading: 01/06/2007

2 Project title: La expresión del receptor de eritropoyetina como factor pronóstico del carcinoma de célulastransicionales de vejigaUniversity issuing the qualification: UniversidadAutónoma de Madrid


Doctorate student: Francisco Antonio Bernabeu AndreuDate of reading: 01/06/2005

Teaching or pedagogic publications, books, articles, etc.

1 Cristóbal Belda Iniesta. Concpetos Básicos en Farmacoeconomía en la Práctica de la Oncología.. You&Us,Material title: Farmacoeconomía para Oncólogos Médicos.Date of creation: 2013Format: Chapters of books

2 Cristóbal Belda Iniesta. Lectura Crítica de Estudios Farmacoeconómicos.. You&Us,Material title: Farmacoeconomía para Oncólogos Médicos.Date of creation: 2013Format: Chapters of books

3 Farmacoeconomía para Oncólogos Médicos.. ISBN 978-84-695-7062-3Material title: Libro CompletoDate of creation: 2013Format: BookRole: Editor or co-editor

4 Manuel González Barón; Javier de Castro Carpeño; Jaime Feliu Batlle; Enrique Espinosa; Pilar Zamora; AmalioOrdóñez; Andres Redondo; Cristóbal Belda. Oncología Clínica. Oncología Clínica. Momento Médico, ISBN978-84-9373-072-7Material title: Libro CompletoDate of creation: 2010Format: Book

5 Cristobal Belda Iniesat; Rosario Perona; Jorge Barriuso. Molecular biology of malignant gliomas.. Springer-VerlagBerlin Heidelberg,Material title: Therapeutic Ribonucleics Acid in Brain TumorsDate of creation: 2009Format: Chapters of books


8

6 Oncología Traslacional.Material title: Novedades en OncologíaDate of creation: 2008Format: Chapters of books

7 Cristobal Belda Iniesta; Rosario Perona. Bases moleculares del tratamiento frente a EGFR. Penymayer,Material title: Tumores cerebralesDate of creation: 2008Format: Chapters of books

8 Cristóbal Belda Iniesta; Rosario Machado Pinilla; Paloma Cejas Guerrero; Javier de Castro Carpeño; ManuelGonzález Barón. Factores moleculares con valor pronóstico en el carcinoma no microcítico de pulmón.. ArsMedica,Material title: Cáncer no microcítico de pulmón: Un reto para el siglo XXI.Date of creation: 2006Format: Chapters of books

9 Jaime Feliu; Enrique Casado Sáenz; Cristóbal Belda Iniesta; Manuel González Barón. Tratamiento médico delcáncer de pulmón: quimioterapia.. Ars Medica,Material title: Cáncer no microcítico de pulmón: Un reto para el siglo XXI.Date of creation: 2006Format: Chapters of books

10 Javier de Castro Carpeño; Cristóbal Belda Iniesta; Enrique Casado Sáenz; Manuel González Barón. Tratamientomédico del cáncer de pulmón: nuevos fármacos.. Ars Medica,Material title: Cáncer no microcítico de pulmón: Un reto para el siglo XXI.Date of creation: 2006

11 Cristóbal Belda Iniesta. Factores pronósticos de toxicidad por quimioterapia. Mc Graw Hill,Material title: Factores pronósticos en Oncología.Date of creation: 2006Format: Chapters of books

12 Javier de Castro Carpeño; Cristóbal Belda Iniesta; Enrique Casado Sáenz; Manuel González Barón. Inhibidoresde ciclo celular. You&Us,Material title: La nueva Oncología Médica: aportación molecular al diagnóstico y tratamiento del cáncerDate of creation: 2006Format: Chapters of books

13 Cristóbal Belda Iniesta; Enrique Casado Sáenz; Javier de Castro Carpeño; María Sereno Moyano; Jaime FeliuBatlle. Inhibidores de la señalización intracelular. You&Us,Material title: La nueva Oncología Médica: aportación molecular al diagnóstico y tratamiento del cáncer.Date of creation: 2006Format: Chapters of books

14 Manuel González Barón; Javier de Castro Carpeño; Jaime Feliu Batlle; Enrique Casado Sáenz; Cristóbal BeldaIniesta. Cáncer no microcítico de pulmón: Un reto para el siglo XXI.. Cáncer no microcítico de pulmón: Un retopara el siglo XXI.. Ars Medica, ISBN 978-84-9751-200-8Material title: Libro CompletoDate of creation: 2006Format: Book


9

15 Jaime Feliu; Cristóbal Belda Iniesta; Montserrat Blanco. La satisfacción del paciente: valoración.. MédicaPanamericana,Material title: Valoración Clínica del Paciente con Cáncer.Date of creation: 2006Format: Chapters of books

16 Manuel González Barón; Cristóbal Belda Iniesta; Javier de Castro Carpeño; Enrique Casado Sáenz. Nutrición ycáncer: investigación clínica y perspectivas futuras.. Arán,Material title: El problema de la nutrición en Oncología ClínicaDate of creation: 2005Format: Chapters of books

17 Cristóbal Belda Iniesta; Elena Hernández Aguado; Manuel González Barón. Caquexia y Cancer: causasrelacionadas con el paciente. Sociedad Española de Oncología Médica,Material title: Guía clínica de caquexia en pacientes con cáncer.Date of creation: 2005Format: Chapters of books

18 Javier de Castro Carpeño; Cristóbal Belda Iniesta; Enrique Casado Sáenz; Manuel González Barón. Carcinomade Pulmón. Médica Panamericana,Material title: Tratado de Medicina Paliativa y Tratamiento de Soporte del Paciente con CáncerDate of creation: 2005Format: Chapters of books

19 Cristóbal Belda Iniesta. Síndrome de anorexia- caquexia: aspectos generales y fisiopatología.. MédicaPanamericana,Material title: Tratado de Medicina Paliativa y Tratamiento de Soporte del Paciente con CáncerDate of creation: 2005Format: Chapters of books

20 Iván Díaz Padilla; Javier de Castro Carpeño; Cristóbal Belda Iniesta; Manuel González Barón. Toxicidad cardiacay pulmonar. Médica Panamericana,Material title: Tratado de Medicina Paliativa y Tratamiento de Soporte del Paciente con CáncerDate of creation: 2005Format: Chapters of books

21 Jaime Feliu; Cristóbal Belda Iniesta. Tratamiento de la anorexia.. Médica Panamericana,Material title: Tratado de Medicina Paliativa y Tratamiento de Soporte del Paciente con CáncerDate of creation: 2005Format: Chapters of books

22 Jaime Feliu; Cristóbal Belda Iniesta. Tratamiento de la astenia. Médica Panamericana,Material title: Tratado de Medicina Paliativa y Tratamiento de Soporte del Paciente con Cáncer.Date of creation: 2005Format: Chapters of books

23 Manuel González Barón; Cristóbal Belda Iniesta. Tratamiento neoadyuvante del cáncer de pulmón no microcítico..Arán,Material title: Casos Clínicos en Oncología Médica.Date of creation: 2004


10

Format: Handbook

24 Manuel González Barón; Cristóbal Belda Iniesta. Tratamiento de soporte. La infección como complicación.Tratamiento del dolor. La nutrición. La anemia.. Scientific Management Communications,Material title: Guía Docente de Oncología Médica.Date of creation: 2004Format: Manual

25 Bases biológicas de la astenia asociada al cáncer (I). Médica Panamericana,Material title: La astenia TumoralDate of creation: 2004Format: Chapters of books

26 Bases biológicas de la astenia asociada al cáncer (II). Médica Panamericana,Material title: La astenia tumoralDate of creation: 2004Format: Chapters of books

27 Cristóbal Belda Iniesta; Javier de Castro Carpeño; Manuel González Barón. Malnutrición y enfermedadneoplásica. You&Us,Material title: Soporte nutricional en el paciente oncológico.Date of creation: 2004Format: Chapters of books

28 Cristóbal Belda Iniesta; Juan Angel Fresno Varas; Paloma Cejas Guerrero; Manuel González Barón. Basesmoleculares de la respuesta a los opioides.. Médica Panamericana,Material title: Dolor y Cáncer: Hacia una Oncología sin dolor.Date of creation: 2003Format: Chapters of books

Experience in science and technology

Scientific or technological activity

Participation in R&D&I projects funded in competitive calls by public or private bodies

1 Name of the project: Glargina induce proliferación tumoral: análisis de la plausibilidad biológica y suaplicación clínica.Institution where project took place: FundaciónHM Hospitales

Type of institution: Foundation

City: Madrid, Community of Madrid, SpainHead(s) researcher(s): Cristóbal Belda IniestaNumber of researchers: 5Funding institution or bodies:FONDO DE INVESTIGACIONES SANITARIAS Type of institution: State agencyCity: MADRID, Community of Madrid, Spain

Start date: 01/01/2012


11

End date: 01/01/2015Total amount: 287.000

2 Name of the project: Red Itemas. NODO DE INNOVACIÓNInstitution where project took place: FUNDACIÓNDE INVESTIGACIÓN HOSPITAL UNIVERSITARIOLA PAZ


City: MADRID, Community of Madrid, SpainNumber of researchers: 15Start date: 01/01/2010End date: 31/12/2013Total amount: 890.000

3 Name of the project: clinical and therapeutic involvement of gene expression profiles from stem- likecancer cells isolated from fresh human colon cancer samples.Institution where project took place: FUNDACIÓNDE INVESTIGACIÓN HOSPITAL UNIVERSITARIOLA PAZ


City: MADRID, Community of Madrid, SpainHead(s) researcher(s): JAIME FELIU BATLLE; CRISTÓBAL BELDA INIESTANumber of researchers: 5Start date: 01/01/2009End date: 31/12/2011

4 Name of the project: Consorcio OncológicaInstitution where project took place: FUNDACIÓNDE INVESTIGACIÓN BIOMÉDICA HOSPITALUNIVERSITARIO LA PAZ


City: MADRID, Community of Madrid, SpainNumber of researchers: 2Start date: 01/01/2008End date: 31/12/2011Total amount: 85.000

5 Name of the project: Analysis of resistance reversal to chemotherapy for non- small cell lung cancer andfunctional genomics by siRNAInstitution where project took place: ConsejoSuperior de Investigaciones Científicas


Head(s) researcher(s): CRISTÓBAL BELDA INIESTA; ROSARIO PERONA ABELLÓNNumber of researchers: 6Total amount: 180.000

6 Name of the project: CENIT ONCNOSISInstitution where project took place: ConsejoSuperior de Investigaciones Científicas


City: MADRID, Community of Madrid, SpainHead(s) researcher(s): JUAN CARLOS LACAL; CRISTÓBAL BELDA INIESTANumber of researchers: 50Funding institution or bodies:Centro para el Desarrollo Tecnológico Industrial Type of institution: BusinessCity: Madrid, Community of Madrid, Spain


12

7 Name of the project: Functional and molecular analysis of JNK/MKP1 pathway for antitumoral activity invitro and in vivo; NFkB inhibitors as single agents or concurrent with chemotherapy.Institution where project took place: ConsejoSuperior de Investigaciones Científicas


Head(s) researcher(s): CRISTÓBAL BELDA INIESTA; ROSARIO PERONA ABELLÓNNumber of researchers: 6Funding institution or bodies:FONDO DE INVESTIGACIONES SANITARIAS Type of institution: State agencyCity: MADRID, Community of Madrid, Spain

Total amount: 135.000

8 Name of the project: Molecular predictive factor for response and resistance to neoadjuvant therapy inrectal cancer: a transcriptomic analysis.Institution where project took place: FUNDACIÓN DE INVESTIGACIÓN HOSPITAL UNIVERSITARIO LAPAZCity: MADRID, Community of Madrid, SpainHead(s) researcher(s): CRISTÓBAL BELDA INIESTA; ENRIQUE CASADO SÁENZNumber of researchers: 5Total amount: 170.000

9 Name of the project: combined PET-CT for non-small cell lung cancer: a cost- effectiveness analysis.Institution where project took place: HospitalUniversitario La Paz


City: MADRID, Community of Madrid, SpainHead(s) researcher(s): NIEVES GÓMEZ LEÓN; Cristóbal Belda IniestaNumber of researchers: 6

Participation in R&D&I non-competitive projects, contracts or agreements with administrationsor public or private bodies

1 Name of the project: Aplicación de Tecnologías de Alto Rendimiento de Análisis Molecular en la deteccióndel Doping en el DeporteRole: Coordinator of total project, network or consortiumNumber of researchers: 8Participating bodies: Comité Olímpico EspañolStart date: 01/10/2013, 5 years

2 Name of the project: CARACTERIZACIÓN DE NANOPARTÍCULAS PARA EL TRATAMIENTO DELGLIOBLASTOMA MULTIFORMERole: Coordinator of total project, network or consortiumNumber of researchers: 4Participating bodies: FUNDACIÓN HM HOSPITALES; FUNDACIÓN IMDEA NANOCIENCIA; RocheFarma, S.A.Start date: 01/07/2013, 1 yearTotal amount: 13.000

3 Name of the project: DESARROLLO DE UN LABORATORIO DE NANOMEDICINARole: Scientific coordinatorHead researcher: RODOLFO MIRANDA SORIANO; CRISTÓBAL BELDA INIESTA


13

Number of researchers: 2Participating bodies: FUNDACIÓN HM HOSPITALES; FUNDACIÓN IMDEA NANOCIENCIAStart date: 01/01/2013, 5 years

4 Name of the project: Evaluación de partículas circulantes en sangre periférica como método diagnósticoen Glioblastoma MultiformeRole: Coordinator of total project, network or consortiumNumber of researchers: 4Participating bodies: FUNDACIÓN HM HOSPITALES; Roche Farma, S.A.Start date: 01/01/2013, 1 yearTotal amount: 30.000

5 Name of the project: COLABORACIÓN DE INVESTIGACIÓN INSTITUTO DE INVESTIGACIONESBIOMÉDICAS "ALBERTO SOLS"Role: Coordinator of total project, network or consortiumHead researcher: ROSARIO PERONA ABELLÓN; CRISTÓBAL BELDA INIESTANumber of researchers: 2Participating bodies: Consejo Superior de Investigaciones Científicas; FUNDACIÓN HM HOSPITALESStart date: 01/06/2012, 5 years

6 Name of the project: Insulin activity on cancer stem-like cellsRole: Scientific coordinatorHead researcher: CRISTÓBAL BELDA INIESTANumber of researchers: 5Participating bodies: Consejo Superior de Investigaciones Científicas; FUNDACIÓN HM HOSPITALES;Sanofi AventisStart date: 01/06/2012, 6 monthsTotal amount: 100.000

7 Name of the project: Insulin activity on cancer stem-like cellsRole: Coordinator of total project, network or consortiumHead researcher: CRISTÓBAL BELDA INIESTANumber of researchers: 4Participating bodies: FUNDACIÓN HM HOSPITALES; Novo Nordisk Pharma, S.A.Start date: 01/01/2012, 1 yearTotal amount: 30.000


14

Results

Intellectual and industrial property. Know-how and industrial secrets

1 Name: HUELLA GENOMICA PARA EL PRONOSTICO DE LA EVOLUCION DE ADENOCARCINOMACOLORECTALInventors/authors/obtainers: y OTROS; CRISTÓBAL BELDA INIESTA; ENRIQUE CASADO SÁENZHolding institution: Universidad Autónoma de MadridApplication number: P200703229.Priority country: SpainDate: 08/02/2010Conferral date: 21/01/2011

2 Name: 11382144.1-12222Inventors/authors/obtainers: y OTROS; CRISTÓBAL BELDA INIESTA; JUAN CARLOS LACALSANJUANHolding institution: Consejo Superior de Investigaciones CientíficasApplication number: EP11382144.1-12222Priority country: Spain

3 Name: EP011382238.1Inventors/authors/obtainers: Y OTROS; JUAN CARLOS LACAL SANJUAN; CRISTÓBAL BELDAINIESTAHolding institution: Consejo Superior de Investigaciones CientíficasApplication number: EP011382238.1Priority country: Spain

4 Name: EP20114524Inventors/authors/obtainers: Y OTROS; JUAN CARLOS LACAL SANJUAN; CRISTÓBAL BELDAINIESTAHolding institution: Consejo Superior de Investigaciones CientíficasApplication number: EP20114524Priority country: Spain


15

Scientific and technological activities

Scientific production

Publications, scientific and technical documents

1 Jorge Oliver-De La Cruz; Josefa Carrión-Navarro; Noemí García Navarro; Antonio Gutiérrez Martín; Elisa LázaroIbáñez; Carmen Escobedo Lucea; Rosario Perona; Cristóbal Belda Iniesta; Angel Ayuso Sacido. SOX2+ cellpopulation from normal human brain white matter is able to generate mature oligodendrocytes.PlosOne. 2014.Type of production: Article Format: Journal

2 M. Cortes-Sempere; M. P. de Miguel; O. Pernia; C. Rodriguez; J. de Castro Carpeno; M. Nistal; E. Conde; F.Lopez-Rios; C. Belda-Iniesta; R. Perona; Caceres II de. IGFBP-3 methylation-derived deficiency mediates theresistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene. 32- 10, pp. 1274 - 83. 2013.Type of production: Article Format: Journal

3 E. Conde; B. Angulo; E. Izquierdo; L. Paz-Ares; C. Belda-Iniesta; M. Hidalgo; F. Lopez-Rios. Lungadenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictivebiomarkers. Clin Transl Oncol. 15 - 7, pp. 503 - 8. 2013.Type of production: Article Format: Journal

4 A. Gutierrez-Gonzalez; C. Belda-Iniesta; J. Bargiela-Iparraguirre; G. Dominguez; P. Garcia Alfonso; R. Perona;I. Sanchez-Perez. Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair.Apoptosis. 18 - 3, pp. 347 - 60. 2013.Type of production: Article Format: Journal

5 E. Conde; B. Angulo; E. Izquierdo; L. Munoz; A. Suarez-Gauthier; C. Plaza; N. Dominguez; M. Torres; L. Madrigal;B. Rubio-Viqueira; C. Belda-Iniesta; M. Hidalgo; F. Lopez-Rios. The ALK translocation in advanced non-small-celllung carcinomas: preapproval testing experience at a single cancer centre. Histopathology. 62 - 4, pp. 609 - 16.2013.Type of production: Article Format: Journal

6 P. Cejas; M. Lopez-Gomez; C. Aguayo; R. Madero; J. Moreno-Rubio; J. de Castro Carpeno; C. Belda-Iniesta; J.Barriuso; V. Moreno Garcia; E. Diaz; E. Burgos; M. Gonzalez-Baron; J. Feliu. Analysis of the concordance in theEGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implicationsfor cancer therapy. Curr Cancer Drug Targets. 12 - 2, pp. 124 - 31. 2012.Type of production: Article Format: Journal

7 C. Belda-Iniesta. Cost-effectiveness, cancer burden and financial crisis: a perfect storm. Clin Transl Oncol. 14 - 10,pp. 713 - 4. 2012.Type of production: Article Format: Journal

8 M. Sereno; P. Cejas; V. Moreno; C. Belda-Iniesta; R. Lopez; M. Nistal; J. Feliu; J. De Castro Carpeno. ERCC1 andtopoisomerase I expression in small cell lung cancer: prognostic and predictive implications. Int J Oncol. 40 - 6, pp.2104 - 10. 2012.Type of production: Article Format: Journal


16

9 M. Sereno; J. De Castro; P. Cejas; M. A. Garcia-Cabezas; C. Belda; E. Casado; J. Feliu; C. Gomez; M. Lopez;M. G. Baron. Expression profile as predictor of relapse after adjuvant treatment in gastric cancer. J GastrointestCancer. 43 - 2, pp. 181 - 9. 2012.Type of production: Article Format: Journal

10 A. Lamarca; N. Hindi; C. Belda-Iniesta; J. de Castro. Foot pain: uncommon presentation of lung cancer. BMJ CaseRep. 2012, 2012.Type of production: Article Format: Journal

11 E. Casado; V. M. Garcia; J. J. Sanchez; M. T. Gomez Del Pulgar; J. Feliu; J. Maurel; B. Castelo; J. MorenoRubio; R. A. Lopez; M. A. Garcia-Cabezas; E. Burgos; J. de Castro; C. Belda-Iniesta; M. Lopez-Gomez; C.Gomez-Raposo; F. Zambrana; M. Sereno; C. Fernandez-Martos; P. Vazquez; J. C. Lacal; M. Gonzalez-Baron; P.Cejas. Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factorand a potential therapeutic target. Int J Radiat Oncol Biol Phys. 84 - 5, pp. 1151 - 8. 2012.Type of production: Article Format: Journal

12 E. Casado; V. M. Garcia; J. J. Sanchez; M. Blanco; J. Maurel; J. Feliu; C. Fernandez-Martos; J. de Castro; B.Castelo; C. Belda-Iniesta; M. Sereno; B. Sanchez-Llamas; E. Burgos; M. A. Garcia-Cabezas; N. Mancenido;R. Miquel; D. Garcia-Olmo; M. Gonzalez-Baron; P. Cejas. A combined strategy of SAGE and quantitative PCRProvides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectalcancer. Clin Cancer Res. 17 - 12, pp. 4145 - 54. 2011.Type of production: Article Format: Journal

13 R. Perona; B. D. Lopez-Ayllon; J. de Castro Carpeno; C. Belda-Iniesta. A role for cancer stem cells in drugresistance and metastasis in non-small-cell lung cancer. Clin Transl Oncol. 13 - 5, pp. 289 - 93. 2011.Type of production: Article Format: Journal

14 V. Moncho-Amor; I. Ibanez de Caceres; E. Bandres; B. Martinez-Poveda; J. L. Orgaz; I. Sanchez-Perez; S.Zazo; A. Rovira; J. Albanell; B. Jimenez; F. Rojo; C. Belda-Iniesta; J. Garcia-Foncillas; R. Perona. DUSP1/MKP1promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. Oncogene. 30 - 6, pp. 668 - 78.2011.Type of production: Article Format: Journal

15 V. M. Garcia; J. F. Batlle; E. Casado; E. Burgos; J. de Castro; C. Belda; J. Barriuso; J. J. Sanchez; M. A.Garcia-Cabezas; M. Gonzalez-Baron; P. Cejas. Immunohistochemical analysis of tumour regression grade forrectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis. 13 - 9, pp. 989 - 98. 2011.Type of production: Article Format: Journal

16 S. C. Gough; C. Belda-Iniesta; C. Poole; M. Weber; D. Russell-Jones; B. F. Hansen; E. Mannucci; J. Tuomilehto.Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedingsfrom a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, heldTuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK. Adv Ther. 28 Suppl5, pp. 1 - 18. 2011.Type of production: Article Format: Journal

17 J. Feliu Batlle; E. Cuadrado; J. Castro; T. Caldes; C. Belda; J. Sastre; J. Barriuso; V. Martinez Marin; E.Diaz-Rubio; M. Gonzalez-Baron. Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreatedmetastatic colorectal cancer patients: a retrospective observational study. Chemotherapy. 57 - 2, pp. 138 - 44.2011.Type of production: Article Format: Journal

18 C. Belda-Iniesta; O. Pernia; R. Simo. Metformin: a new option in cancer treatment. Clin Transl Oncol. 13 - 6, pp.363 - 7. 2011.Type of production: Article Format: Journal


17

19 C. Belda-Iniesta; I. Ibanez de Caceres; J. de Castro. Monoclonal antibodies for medical oncology: a few criticalperspectives. Clin Transl Oncol. 13 - 2, pp. 84 - 7. 2011.Type of production: Article Format: Journal

20 J. Feliu; P. Borrega; A. Leon; L. Lopez-Gomez; M. Lopez; J. Castro; C. Belda-Iniesta; J. Barriuso; V. Martinez; M.Gonzalez-Baron. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advancedpancreatic cancer. Cancer Chemother Pharmacol. 67 - 1, pp. 215 - 21. 2011.Type of production: Article Format: Journal

21 C. Belda-Iniesta; J. de Castro; R. Perona. Translational proteomics: what can you do for true patients?. JProteome Res. 10 - 1, pp. 101 - 4. 2011.Type of production: Article Format: Journal

22 J. de Castro-Carpeno; R. Perona; C. Belda-Iniesta. Treatment for ALK-mutated non-small-cell lung cancer: a newmiracle in the research race. Clin Transl Oncol. 13 - 11, pp. 774 - 9. 2011.Type of production: Article Format: Journal

23 A. Peralta-Sastre; C. Manguan-Garcia; A. de Luis; C. Belda-Iniesta; S. Moreno; R. Perona; I. Sanchez-Perez.Checkpoint kinase 1 modulates sensitivity to cisplatin after spindle checkpoint activation in SW620 cells. Int JBiochem Cell Biol. 42 - 2, pp. 318 - 28. 2010.Type of production: Article Format: Journal

24 I. Ibanez de Caceres; M. Cortes-Sempere; C. Moratilla; R. Machado-Pinilla; V. Rodriguez-Fanjul; C.Manguan-Garcia; P. Cejas; F. Lopez-Rios; L. Paz-Ares; J. de CastroCarpeno; M. Nistal; C. Belda-Iniesta; R.Perona. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.Oncogene. 29 - 11, pp. 1681 - 90. 2010.Type of production: Article Format: Journal

25 E. Hernando; J. Sarmentero-Estrada; T. Koppie; C. Belda-Iniesta; V. Ramirez de Molina; P. Cejas; C. Ozu; C.Le; J. J. Sanchez; M. Gonzalez-Baron; J. Koutcher; C. Cordon-Cardo; B. H. Bochner; J. C. Lacal; A. Ramirez deMolina. A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. Oncogene. 28 - 26,pp. 2425 - 35. 2009.Type of production: Article Format: Journal

26 J. Feliu; M. Sereno; J. D. Castro; C. Belda; E. Casado; M. Gonzalez-Baron. Chemotherapy for colorectal cancer inthe elderly: Whom to treat and what to use. Cancer Treat Rev. 35 - 3, pp. 246 - 54. 2009.Type of production: Article Format: Journal

27 I. Sanchez-Perez; P. Garcia Alonso; C. Belda Iniesta. Clinical impact of aneuploidy on gastric cancer patients. ClinTransl Oncol. 11 - 8, pp. 493 - 8. 2009.Type of production: Article Format: Journal

28 J. Feliu; J. L. Firvida; J. Castro; C. Madronal; A. Rodriguez-Jaraiz; M. Salgado; C. Belda-Iniesta; E. Casado; J.Garcia-Mata; M. Gonzalez-Baron. Combination therapy with docetaxel and low dose of cisplatin in elderly patientswith advanced non-small cell lung cancer: multicenter phase II study. Cancer Chemother Pharmacol. 63 - 3, pp.403 - 9. 2009.Type of production: Article Format: Journal

29 M. Sereno; J. De Castro; C. Belda-Iniesta; M. A. Garcia-Cabezas; P. Cejas; E. Casado; J. Barriuso; J. Feliu; J.Larrauri. EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiationtreatment. Pathol Oncol Res. 15 - 1, pp. 1 - 10. 2009.Type of production: Article Format: Journal


18

30 P. Cejas; M. Lopez-Gomez; C. Aguayo; R. Madero; J. de Castro Carpeno; C. Belda-Iniesta; J. Barriuso; V. MorenoGarcia; J. Larrauri; R. Lopez; E. Casado; M. Gonzalez-Baron; J. Feliu. KRAS mutations in primary colorectalcancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One. 4 - 12, pp.e8199 - e8199. 2009.Type of production: Article Format: Journal

31 M. Cortes-Sempere; S. Chattopadhyay; A. Rovira; V. Rodriguez-Fanjul; C. Belda-Iniesta; M. Tapia; P. Cejas;R. Machado-Pinilla; C. Manguan-Garcia; I. Sanchez-Perez; M. Nistal; C. Moratilla; J. de Castro-Carpeno;M. Gonzalez-Baron; J. Albanell; R. Perona. MKP1 repression is required for the chemosensitizing effects ofNF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cancer Lett. 286 - 2, pp. 206 - 16. 2009.Type of production: Article Format: Journal

32 V. Moreno Garcia; P. Cejas; M. Blanco Codesido; J. Feliu Batlle; J. de Castro Carpeno; C. Belda-Iniesta; J.Barriuso; J. J. Sanchez; J. Larrauri; M. Gonzalez-Baron; E. Casado. Prognostic value of carcinoembryonic antigenlevel in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 24 - 7, pp. 741 - 8. 2009.Type of production: Article Format: Journal

33 R. E. Kast; C. Belda-Iniesta. Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibitionwith chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis. Curr Stem Cell Res Ther. 4 - 4, pp.314 - 7. 2009.Type of production: Article Format: Journal

34 J. D. Castro-Carpeno; M. S. Moyano; E. C. Saenz; C. Belda-Iniesta; J. F. Batlle; M. G. Baron.WITHDRAWN:Bevacizumab: a safe and effective treatment in a patient with advanced colorectal cancer andrepeated removal of metastases. Anticancer Drugs. 20 Special Issue 1, pp. S7 - S10. 2009.Type of production: Article Format: Journal

35 C. Belda-Iniesta; E. C. Saenz; J. de Castro-Carpeno; E. Hernandez; M. G. Baron. WITHDRAWN:Completeand rapid response to FOLFIRI plus bevacizumab in a patient presenting with impaired liver function and poorperformance status from colon cancer liver metastases. Anticancer Drugs. 20 Special Issue 1, pp. S11 - S12.2009.Type of production: Article Format: Journal

36 M. Sereno Moyano; E. Casado Saenz; J. de Castro-Carpeno; C. Belda-Iniesta. WITHDRAWN:The combinationof FOLFOX4 and bevacizumab may enable salvage surgery of unresectable liver metastases in colon cancer.Anticancer Drugs. 20 Special Issue 1, pp. S4 - S6. 2009.Type of production: Article Format: Journal

37 M. Sereno; A. Brunello; A. Chiappori; J. Barriuso; E. Casado; C. Belda; J. de Castro; J. Feliu; M. Gonzalez-Baron.Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol. 10 - 1, pp. 35 - 46. 2008.Type of production: Article Format: Journal

38 J. de Castro-Carpeno; C. Belda-Iniesta; E. Casado Saenz; E. Hernandez Agudo; J. Feliu Batlle; M. GonzalezBaron. EGFR and colon cancer: a clinical view. Clin Transl Oncol. 10 - 1, pp. 6 - 13. 2008.Type of production: Article Format: Journal

39 J. de Castro; C. Belda-Iniesta; D. Isla; M. Domine; A. Sanchez; E. Batiste; M. G. Baron. Early interventionwith epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: asubgroup analysis of the NeoPrevent study. Lung Cancer. 59 - 2, pp. 211 - 8. 2008.Type of production: Article Format: Journal


19

40 C. Belda-Iniesta; J. de Castro Carpeno; M. Sereno; M. Gonzalez-Baron; R. Perona. Epidermal growth factorreceptor and glioblastoma multiforme: molecular basis for a new approach. Clin Transl Oncol. 10 - 2, pp. 73 - 7.2008.Type of production: Article Format: Journal

41 C. Belda-Iniesta; I. Ibanez de Caceres; J. Barriuso; J. de Castro Carpeno; M. Gonzalez Baron; J. Feliu. Molecularbiology of pancreatic cancer. Clin Transl Oncol. 10 - 9, pp. 530 - 7. 2008.Type of production: Article Format: Journal

42 C. Gomez-Raposo; M. Nistal; J. De Castro Carpeno; G. Sosa Rotundo; C. Belda-Iniesta; E. Casado; M. GonzalezBaron. Retroperitoneal Castleman's disease with colon cancer. A rare association. Clin Transl Oncol. 10 - 4, pp.238 - 40. 2008.Type of production: Article Format: Journal

43 R. Perona; V. Moncho-Amor; R. Machado-Pinilla; C. Belda-Iniesta; I. Sanchez Perez. Role of CHK2 in cancerdevelopment. Clin Transl Oncol. 10 - 9, pp. 538 - 42. 2008.Type of production: Article Format: Journal

44 M. Gonzalez Baron; M. Feyjoo; J. Carulla Torrent; C. Camps; Y. Escobar; C. Belda-Iniesta. Study of theprevalence of tumour-related asthenia in Spanish cancer patients. Clin Transl Oncol. 10 - 6, pp. 351 - 8. 2008.Type of production: Article Format: Journal

45 A. Ramirez de Molina; J. Sarmentero-Estrada; C. Belda-Iniesta; M. Taron; V. Ramirez de Molina; P. Cejas; M.Skrzypski; D. Gallego-Ortega; J. de Castro; E. Casado; M. A. Garcia-Cabezas; J. J. Sanchez; M. Nistal; R. Rosell;M. Gonzalez-Baron; J. C. Lacal. Expression of choline kinase alpha to predict outcome in patients with early-stagenon-small-cell lung cancer: a retrospective study. Lancet Oncol. 8 - 10, pp. 889 - 97. 2007.Type of production: Article Format: Journal

46 C. Belda-Iniesta; R. Perona; C. Carpeno Jde; P. Cejas; E. Casado; C. Manguan-Garcia; I. Ibanez de Caceres; I.Sanchez-Perez; F. B. Andreu; J. A. Ferreira; A. Aguilera; J. de la Pena; E. Perez-Sanchez; R. Madero; J. Feliu; M.Sereno; M. Gonzalez-Baron. Human recombinant erythropoietin does not promote cancer growth in presence offunctional receptors expressed in cancer cells. Cancer Biol Ther. 6 - 10, pp. 1600 - 5. 2007.Type of production: Article Format: Journal

47 E. Casado; J. De Castro; C. Belda-Iniesta; P. Cejas; J. Feliu; M. Sereno; M. Gonzalez-Baron. Molecular markers incolorectal cancer: genetic bases for a customised treatment. Clin Transl Oncol. 9 - 9, pp. 549 - 54. 2007.Type of production: Article Format: Journal

48 C. Belda-Iniesta; J. de Castro Carpeno; J. A. Carrasco; V. Moreno; E. Casado Saenz; J. Feliu; M. Sereno; F.Garcia Rio; J. Barriuso; M. Gonzalez Baron. New screening method for lung cancer by detecting volatile organiccompounds in breath. Clin Transl Oncol. 9 - 6, pp. 364 - 8. 2007.Type of production: Article Format: Journal

49 P. Cejas; M. A. Garcia-Cabezas; E. Casado; C. Belda-Iniesta; J. De Castro; J. A. Fresno; M. Sereno; J. Barriuso;E. Espinosa; P. Zamora; J. Feliu; A. Redondo; D. A. Hardisson; J. Renart; M. Gonzalez-Baron. Phospholipidhydroperoxide glutathione peroxidase (PHGPx) expression is downregulated in poorly differentiated breastinvasive ductal carcinoma. Free Radic Res. 41 - 6, pp. 681 - 7. 2007.Type of production: Article Format: Journal

50 M. Gonzalez Baron; M. A. Lacasta Reverte; A. Ordonez Gallego; C. Belda-Iniesta. Control of oncologic pain inrelief of suffering. Our experience. Clin Transl Oncol. 8 - 7, pp. 525 - 32. 2006.Type of production: Article Format: Journal


20

51 J. Feliu; G. Martin; J. Castro; A. Sundlov; A. Rodriguez-Jaraiz; E. Casado; M. Lomas; C. Madronal; A. Galan; C.Belda; M. Gonzalez-Baron. Docetaxel and mitomycin as second-line treatment in advanced non-small cell lungcancer. Cancer Chemother Pharmacol. 58 - 4, pp. 527 - 31. 2006.Type of production: Article Format: Journal

52 M. Sereno; M. A. Garcia-Cabezas; J. De Castro; P. Cejas; E. C. Saenz; C. Belda-Iniesta; J. B. Feijoo; J. Larrauri;M. Nistal; M. G. Baron. Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin,and E-cadherin in non tumoral gastric mucous membrane. Eur J Histochem. 50 - 4, pp. 285 - 92. 2006.Type of production: Article Format: Journal

53 C. Belda-Iniesta; C. Carpeno Jde; E. C. Saenz; M. Gutierrez; R. Perona; M. G. Baron. Long term responses withcetuximab therapy in glioblastoma multiforme. Cancer Biol Ther. 5 - 8, pp. 912 - 4. 2006.Type of production: Article Format: Journal

54 S. Chattopadhyay; R. Machado-Pinilla; C. Manguan-Garcia; C. Belda-Iniesta; C. Moratilla; P. Cejas; J. A.Fresno-Vara; J. de Castro-Carpeno; E. Casado; M. Nistal; M. Gonzalez-Baron; R. Perona. MKP1/CL100 controlstumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene. 25 - 23, pp. 3335 - 45. 2006.Type of production: Article Format: Journal

55 C. Belda-Iniesta; J. de Castro Carpeno; E. Casado Saenz; P. Cejas Guerrero; R. Perona; M. Gonzalez Baron.Molecular biology of malignant gliomas. Clin Transl Oncol. 8 - 9, pp. 635 - 41. 2006.Type of production: Article Format: Journal

56 A. Isidoro; E. Casado; A. Redondo; P. Acebo; E. Espinosa; A. M. Alonso; P. Cejas; D. Hardisson; J. A. FresnoVara; C. Belda-Iniesta; M. Gonzalez-Baron; J. M. Cuezva. Breast carcinomas fulfill the Warburg hypothesis andprovide metabolic markers of cancer prognosis. Carcinogenesis. 26 - 12, pp. 2095 - 104. 2005.Type of production: Article Format: Journal

57 P. Cejas; M. A. Garcia-Cabezas; E. Casado; J. Barriuso; J. A. Fresno; E. Diaz; C. Belda-Iniesta; J. Castro; E.Espinosa; P. Zamora; J. Feliu; A. Redondo; D. A. Hardisson; M. Gonzalez-Baron. Localisation of COX-2 protein isdifferent in breast ductal carcinoma and adjacent non-tumour ductal epithelium. Clin Transl Oncol. 7 - 6, pp. 239 -43. 2005.Type of production: Article Format: Journal

58 M. Sereno Moyano; E. Casado Saenz; C. Belda Iniesta; M. Gonzalez Baron. Subacute dementia as presentingfeature of carcinomatous leptomeningeal metastases. Clin Transl Oncol. 7 - 1, pp. 29 - 30. 2005.Type of production: Article Format: Journal

59 C. Belda-Iniesta; R. Perona; J. de Castro Carpeno; S. Chattopadhyay; E. Casado; P. Cejas; J. A. Fresno Vara; C.Moreno Guerra; M. Gonzalez Baron. Do beta-tubulin pseudogenes really matter?. Lancet Oncol. 5 - 5, pp. 271 - 2.2004.Type of production: Article Format: Journal

60 E. Casado; J. De Castro; C. Belda-Iniesta; J. Feliu; M. Gonzalez-Baron; W. Arafat. Doomed trials for promisingadenoviruses: a rationale for success. J Clin Oncol. 22 - 6, pp. 1162 - 4. 2004.Type of production: Article Format: Journal

61 P. Cejas; E. Casado; C. Belda-Iniesta; J. De Castro; E. Espinosa; A. Redondo; M. Sereno; M. A. Garcia-Cabezas;J. A. Vara; A. Dominguez-Caceres; R. Perona; M. Gonzalez-Baron. Implications of oxidative stress and cellmembrane lipid peroxidation in human cancer (Spain). Cancer Causes Control. 15 - 7, pp. 707 - 19. 2004.Type of production: Article Format: Journal


21

62 J. A. Fresno Vara; E. Casado; J. de Castro; P. Cejas; C. Belda-Iniesta; M. Gonzalez-Baron. PI3K/Akt signallingpathway and cancer. Cancer Treat Rev. 30 - 2, pp. 193 - 204. 2004.Type of production: Article Format: Journal

63 C. Belda-Iniesta; R. M. Sanchez-Aquino Gonzalez; E. Cuesta; M. Gonzalez-Baron. Atrioventricular nodal blockingsecondary to melanoma infiltration. Melanoma Res. 13 - 4, pp. 433 - 4. 2003.Type of production: Article Format: Journal

64 C. Belda-Iniesta; J. de Castro Carpeno; J. A. Fresno Vara; P. Cejas Guerrero; E. Casado Saenz; E. EspinosaArranz; A. Redondo Sanchez; J. Feliu Battle; M. Gonzalez Baron. Eicosapentaenoic acid as a targeted therapy forcancer cachexia. J Clin Oncol. 21 - 24, pp. 4657 - 8; author reply 4658. 2003.Type of production: Article Format: Journal

65 J. de Castro; C. Belda-Iniesta; P. Cejas; E. Casado; J. A. Fresno Vara; D. Hardisson; J. J. Sanchez; J. Feliu; A.Ordonez; M. Nistal; M. Gonzalez-Baron. New insights in beta-tubulin sequence analysis in non-small cell lungcancer. Lung Cancer. 41 - 1, pp. 41 - 8. 2003.Type of production: Article Format: Journal

66 C. Belda-Iniesta; E. Casado; M. Corral de la Calle; B. Castelo; M. G. Baron. Re: Folliculitis associated with weeklypaclitaxel treatment. J Natl Cancer Inst. 95 - 5, pp. 410 - 410. 2003.Type of production: Article Format: Journal

67 BD López-Ayllon; V Moncho-Amor; A Abarrategi; II de Cáceres; J Castro-Carpeño; C Belda-Iniesta; R Perona;R Perona; L Sastre. Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell linesconstitute related cell populations.Cancer Med.Type of production: Article Format: Journal

Work presented in conferences at the national or international level

1 Title: GBM cell microvesicles carrying gDNA oncogenic sequences cross the BBB and reach the peripheralblood.Name of the conference: 2014 ASCO Annual MeetingCity: Chicago, United States of AmericaDate: 30/05/2014End date: 03/06/2014Esther Holgado; Noemi García Romero; Josefa Garcia Carrión; Elisa Lazaro Ibañez; Carmen Escobedo;Cristina Gonzalez Perez; Pilar Sanchez; Marta Alonso; Lorea Materola; Ricardo Prat; Cristóbal BeldaIniesta; Angel Ayuso Sacido.

2 Title: High level of suppressor-of-fused (SuFu) expression and tumor cells dissemination in humanglioblastoma.Name of the conference: 2014 ASCO Annual MeetingCity: Chicago, United States of AmericaDate: 2014End date: 2014Noemi García Romero; María Perís Celda; Cristina Zahonero; Carmen Escobedo; Pilar Sanhez; CristinaGonzález Perez; Esther Holgado; Ricardo Prat; Cristóbal Belda Iniesta; Angel Ayuso Sacido.

3 Title: Bevacizumab in combination with TMZ in patients with recurrent GBM: Final OS and PFS analysis.Name of the conference: ASCO Annual MeetingDate: 2013


22

Juan Manuel Sepulveda; C. B.-I.; Miquel Gil; Pedro Pérez Segura; Alfonso Berrocal; Gaspar Reynes; OscarGallego; Jose Manuel Ordonez; Beatriz La Orden; Carmen Balana. 2013.

4 Title: High expression levels of CD90 to predict edema response to steroid treatment in glioblastomamultiforme (GBM) patients.Name of the conference: ASCO Annual MeetingDate: 2013Cristobal Belda-Iniesta; E. H.; Ricardo Hitt; Ricardo Prat; Javier De Castro; Inmaculada Ibañez de Cáceres;Rosario Perona; Angel Ayuso Sacido. 2013.

5 Title: Insulin analogues to stimulate cell growth in human cancer initiating cells (CICs).Name of the conference: ASCO Annual MeetingDate: 2013Esther Holgado; M. C. S.; Olga Pernia; Olatz Arrizabalaga; Inmaculada Ibañez de Cáceres; Ricardo Hitt;Javier De Castro; Angel Ayuso Sacido; Rosario Perona; Cristobal Belda-Iniesta. 2013.

6 Title: Role of IGF-1/IGFBP3 in non-small cell lung cancer sensitivity to therapy.Name of the conference: ASCO Annual MeetingDate: 2013Inmaculada Ibañez de Cáceres; E. H.; Olga Pernia; Javier De Castro; Ricardo Hitt; Esther Conde; FernandoLópez-Ríos; Maria Cortes Semperes; Rosario Perona; Cristobal Belda-Iniesta. 2013.

7 Title: Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancertherapies in Spain.Name of the conference: ASCO Annual MeetingDate: 2012Victor Moreno; B. M.-A.; Jorge Barriuso; Laura Mezquita; Inmaculada Ibañez de Cáceres; Angel AyusoSacido; Jose Maria Peña; Rosario Perona; Cristobal Belda-Iniesta. 2012.

8 Title: Cost-effectiveness analysis per life-year gained based on predictors of response for first-linemetastatic colorectal cancer therapy in Spain.Name of the conference: ASCO Annual MeetingDate: 2012Cristobal Belda-Iniesta; V. M.; Brezo Martinez-Amores; Jorge Barriuso; Laura Mezquita; Inmaculada Ibañezde Cáceres; Angel Ayuso Sacido; Jose Maria Peña; Rosario Perona. 2012.

9 Title: Integrated next-generation sequencing and patient-derived xenografts to personalized cancertreatment.Name of the conference: ASCO Annual MeetingDate: 2012Elena Garralda; A. C.; Fernando López-Ríos; Siân Jones; Lisa M. Kann; Samuel V. Angiuoli; Luis A. Diaz;Jr.; Victor E. Velculescu; Pedro P. López-Casas; Francesca Sarno; Raquel Martinez; Carlos Gomez-Martin;Esther Conde; Cristobal Belda-Iniesta; Alfonso Valencia; Manuel Hidalgo. 2012.

10 Title: Pharmacoeconomic analysis for K-Ras status–based decisions for first-line therapy of metastaticcolorectal cancer (mCRC) in Spain.Name of the conference: ASCO Gastrointestinal Cancers SymposiumDate: 2012Belda; C.2012.


23

11 Title: Phase I trial in advanced refractory solid tumors of the new drug first-in-class PDM08.Name of the conference: ASCO Annual MeetingDate: 2012Jorge Barriuso; V. M.; Monica Coronado; Ignacio Galicia; Irene Soria; Javier de Castro; CristobalBelda-Iniesta; Virginia Martinez Marín; Ana Custodio; Andres Redondo; Angela Lamarca; Nadia Hindi; JoseLuis Subiza; Jesus Frias; Jaime Feliu; Antonio Carcas. 2012.

12 Title: Year-to-year impact budget analysis of biologic therapies for first-line metastatic colorectal cancer(mCRC) therapy in Spain.Name of the conference: ASCO Annual MeetingDate: 2012Brezo Martinez-Amores; L. M.; Inmaculada Ibañez de Cáceres; Angel Ayuso Sacido; Jose Maria Peña;Rosario Perona; Cristobal Belda-Iniesta. 2012.

13 Title: Study on the deterioration of verbal memory in colon cancer patients after receiving adjuvantchemotherapy.Name of the conference: ASCO Gastrointestinal Cancers SymposiumDate: 2011V. Martinez Marín; S. L. S.; J. De Castro; J. A. Cruzado; C. Belda-Iniesta; J. Cano; J. Barriuso Feijoo; M.Feliu; J. Smith; J. Feliu. 2011.

14 Title: A combined strategy of serial analysis of gene expression (SAGE) and quantitative PCR (qPCR) toidentify four genes that predict outcome in non-small cell lung cancer patients.Name of the conference: ASCO Annual MeetingDate: 2010J. De Castro; C. B.-I.; J. Sanchez; R. Machado-Pinilla; V. Rodríguez-Fanjúl; J. Feliu; I. Ibañez de Cáceres;M. Nistal; R. Perona; P. Cejas.2010.

15 Title: A multicenter phase II study evaluating erlotinib in combination with a fixed-dose rate infusion ofgemcitabine (GEM) in advanced pancreatic cancer (APC).Name of the conference: ASCO Gastrointestinal Cancers SymposiumDate: 2010J. Feliu Batlle; P. B.; A. Leon Carbonero; L. López; M. Lopez; J. De Castro; C. Belda-Iniesta; J. Barriuso; V.Martinez; M. Gonzalez-Baron. 2010.

16 Title: Analysis of EGFR pathway mediators in KRAS wild-type primary tumors is not representative of theirstatus in related metastases.Name of the conference: ASCO Annual MeetingDate: 2010P. Cejas; M. L.-G.; C. Aguayo; R. Madero; J. De Castro; C. Belda-Iniesta; J. Barriuso; E. Burgos; M.Gonzalez-Baron; J. Feliu. 2010.

17 Title: Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastaticsamples considering clinicopathological features.Name of the conference: ASCO Annual MeetingDate: 2009P. Cejas; R. Madero; J. De Castro; E. Casado; C. Belda; J. Larrauri; J. Barriuso; M. González-Barón; J.Feliú. 2009.

18 Title: Immunohistochemical analysis of tumor regression grade for rectal cancer after neoadjuvantchemoradiotherapy.Name of the conference: ASCO Annual Meeting


24

Date: 2009V. Moreno Garcia; J. Feliu; J. De Castro; C. Belda-Iniesta; J. Barriuso; J. Larrauri; M. Gonzalez Baron; E.Casado. 2009.

19 Title: Is hepcidin involved in anemia of advanced non-small cell lung carcinoma (NSCLC) patients treatedwith platin-based chemotherapy- An exploratory studyName of the conference: ASCO Annual MeetingDate: 2009J. De Castro; C. Belda-Iniesta; N. Ramirez-Merino; J. Barriuso; E. Hernandez-Agudo; J. Feliu; V.Moreno-Garcia; V. Martinez-Marin; M. Gonzalez-Baron. 2009.

20 Title: Outcome predictors in rectal cancer treated with neoadjuvant chemoradiotherapy.Name of the conference: ASCO Gastrointestinal Cancers Symposium.Date: 2009V. Moreno Garcia; M. Blanco; J. Feliu Batlle; J. de Castro; C. Belda-Iniesta; J. Barriuso; J. Sanchez; M.Gonzalez Baron; E. Casado Saez. 2009.

Experience in R&D&I management and participation in scientific committees

Scientific advisory committees, scientific societies

1 Committee title: Wellbeing of Women FoundationInstitution which it depends on: Wellbeing ofWomen Foundation

Type of institution: Associations and Groups

City: United KingdomStart date: 01/01/2011 - 31/01/2011

2 Committee title: Andalusian BiobankInstitution which it depends on: Junta de AndaluciaCity: Andalusia, SpainStart date: 01/02/2013

3 Committee title: National Agency for EvaluationPrimary (UNESCO code): 320101 - CancerologyInstitution which it depends on: MINECO Type of institution: Administrative Body of the

National Health SystemCity: SpainStart date: 01/01/2012

4 Committee title: National Strategic Committee for R&D Projects.Area of the activity: NationalPrimary (UNESCO code): 320101 - CancerologyCity: SpainInstitution which it depends on: National Institute of Health "Carlos III"Start date: 01/06/2008


25

Experience organising R&D&I activities

Title: Brain Tumors GroupType of activity: Translational Research Lab Area of the activity: Non EU InternationalConvening institution: Severiano Ballesteros Foundation- Centro Nacional de Investigaciones OncológicasCity: Madrid, Community of Madrid, SpainStart date: 01/11/2011

R&D&I management experience

1 Title/name of the activity: NanoMedicina LabType of management: Group managementResponsibility held: Scientific Directorinstitution: FUNDACIÓN IMDEA NANOCIENCIAStart date: 01/03/2013

2 Title/name of the activity: Results of Research Transference Office (OTRI)Type of management: Management of bodyResponsibility held: Directorinstitution: Fundación de Investigacion Hospital Universitario La PazStart date: 01/01/2012

3 Title/name of the activity: Severiano Ballesteros FoundationType of management: Coordination FSB and CNIO for brain tumour lab.Responsibility held: Scientific Directorinstitution: Centro Nacional de InvestigacionesOncológicas



4 Title/name of the activity: Innovation UnitType of management: Management of R&D&I actions and projectsResponsibility held: Directorinstitution: Fundación de Investigación HospitalUniversitario La Paz



5 Title/name of the activity: International Summits Seve Ballesteros FoundationType of management: Management of organised eventsResponsibility held: Scientific Directorinstitution: Seve Ballesteros FoundationStart date: 01/01/2010


26

Experience in assessment and review of R&D&I projects and articles

1 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: British Journal of CancerType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition

Area: European Union

2 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Biochemical PharmacologyType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition

Area: Non EU International

3 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Cancer Biology and TherapyType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


4 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Cancer LettersType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


5 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Clinical Cancer ResearchType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


6 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Clinical and Translational OncologyType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


7 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Current Pharmaceutical DesignType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition



27

8 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Journal of Cellular and Molecular MedicineType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


9 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Journal of Translational MedicineType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


10 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Journal of the National Cancer InstituteType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


11 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Molecular Cancer TherapeuticsType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


12 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: PLoS ONEType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


13 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: Translational ResearchType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition


14 Name of the activity: Review of submitted manuscriptsResponsibility held: ReviewerOrganising institution: World Journal of SurgeryType of activity: Review of articles in scientific or technological journalsAccess system: Designated by the correspondingparty without competition



28

Other achievements

Stays in public or private R&D&I centres

institution: Consejo Superior de InvestigacionesCientíficas


Faculty, institute or centre: Instituto de Investigaciones Biomédicas Alberto SolsCity: Madrid, Community of Madrid, SpainStart date: 01/09/2003End date: 01/02/2012Aims of the stay: Post-doctoral

cvn - cristobal belda iniesta - intheos · residency program, to incorporate them into a 3-year...

Documents